The "Arterium" Corporation 01032, Kiev, Saksaganskogo Street, 139 Tel: (+380 44) 490 75 22 Fax: (+380 44) 490 75 17 Chief Executive Officer: Dennis Gartsylov The "Arterium" Corporation - one of the leading Ukrainian pharmaceutical companies, which operates in the industry that cares about the most important values - health and preservation of human life. Established in 2005, the "Arterium" Corporation brings together two Ukrainian companies with more than a century and a half tradition of medicine manufacturing: JSC "Kyivmedpreparat" - the largest Ukrainian producer of antibacterial drugs and JSC "Halychpharm" - leader in production of plant-based medications. The Ukrainian market is the essential one for the entire Corporation’s activity. At the same time to ensure marketing activities on the external markets the Corporation has opened its representative offices in CIS countries such as: Russia, Belarus, Kazakhstan and Uzbekistan. A key focus of the "Arterium" Corporation is the production, marketing and distribution of modern, efficient, safe and high quality medicines to ensure a long and productive life. Currently we manufacture over 140 generic and several original drugs in 10 of 14 ATC groups. In the range of the Corporation products there are a number of original medicines: Thiotriazolin®, L-lysine aescinat®, Tiocetam® and Urolesan®. All of them have received the recognition and trust of the medical community because of their efficiency and proven quality. We pay close attention to the needs of patients, health care system and produce the modern generic drugs which have proved to the world medical and clinical practice. Thanks to affordable price and high quality, which have been confirmed by the certification of production, our drugs will make it possible to raise to a higher level the quality of treatment of a wider patients range making it closer to international high standards. We are also constantly exploring therapeutic needs and direct our efforts to find and develop original products, convenient to administrate combinations of known substances, as well as new plant – based drugs. For the period of 2009 -2011 there have been issued more than 40 new drugs (including forms and dosages). For the period of 2012-2014 we are planning to release about 90 new medicines. All products issued by the Corporation in recent years have undergone a number of required studies to comply with European quality standards and have proven their efficiency. Since 2007, the Corporation has been regularly conducting clinical trials of their drugs. The trials are aimed at proving the equivalence of generic drugs produced by the Corporation versus more expensive original drugs through bioequivalence studies and therapeutic equivalence. We keep making all required preclinical and clinical studies having got our traditional as well as new and original drugs in the Corporation’s product portfolio. These studies provide the evidence base indicating the efficacy and safety of our products. All trials
are conducted in accordance with national and European legislation, as well as mandatory compliance with the ethical principles of clinical trials. Along with the manufacturing, marketing and distribution of traditional medicines, the Corporation has started manufacturing and marketing of recombinant (genetically engineered) medicines. According to the 2010 sales results in Ukraine the Corporation has demonstrated leadership in the antibiotic group and dermatological medicines, and also has taken a leadership position in the group of medicines for the treatment of cardio - vascular and nervous systems. The leaders of sales in their target segments are: Thiotriazolin ® - for the treatment of coronary heart disease Amoxil ®, Azimed ®, Gepacef ® - antibiotics Sonnat ® - treatments for sleep disorders Tiocetam ® - medicines opposing the cerebrovascular disease Diflyuzol ® - a group of antifungal drugs Gerpevir ® - medicines opposing herpes. The enterprises - members of the Corporation, operating under "ARTERIUM" brand produce medicines known for their quality, both in Ukraine and abroad. Quality management systems of the enterprises that are members of the "ARTERIUM" corporation meet the international standard of environmental management DSTU ISO 14001:2006. The production facilities of JSC "Kyivmedpreparat" and JSC "Halychpharm" have been certified for compliance with Good Manufacturing Practice (GMP). We strive to establish harmonious, trusting and lasting relationships with all groups and target audiences that are affected by our activities. In addition to output, which rescues and helps to maintain human health and life, we recognize the importance of social, regulatory and environmental issues and harmonious coexistence with all organizations and individuals who interact with us. As a powerful Ukrainian pharmaceutical manufacturer, we strive to bring as much benefit to our country, its people and society as possible. The policy of corporate social responsibility initiative includes the Corporation "ARTERIUM" - For a Healthy Lifestyle!" Programs of this initiative include not only our staff but also doctors, pharmacists and consumers. As business leaders, we aim to draw public attention to this issue and additionally we are taking certain measures to increase the number of the healthy lifestyle initiative followers. JSC "Kyivmedpreparat" JSC "Kyivmedpreparat" remains undisputable national leader in the production of antibacterial drugs. The plant is one of the largest pharmaceutical industries in Ukraine, as well as the most experienced venture of chemical and pharmaceutical industry in the country with its creation falling into the middle of the XIX th century.
Today the plant produces about 100 generic and original medicines. Since 1847 the company has been producing drugs in the following forms of production: injection in vials, tablets, capsules, ointments, gels. JSC "Halychpharm" JSC "Halychpharm" has a unique experience in the field of phytochemical production of finished drugs and extraction of vegetable substances for the production of medicines. The history of this company has more than 100 years. Since 1911 the company produces medicines in the following forms: injections in ampoules, tablets, solutions, extracts, syrups. The plant manufactures about 50 generic and original medicines.
Lazard Global Thematic Equity Performance (Gross of fees; through 31 January 2014) Performance reported gross of fees. Past performance is not necessarily indicative of future performance. Benchmark returns MSCI net official numbers. Source: MSCI. Based on a representative account. Commentary Market Overview Equity markets swooned in January. The emerging markets fell most as capital
Major languages: French, indigenous languages Major religions: Indigenous beliefs, Islam, Christianity Life expectancy: 47 years (men), 48 years (women) (UN) Monetary unit: 1 CFA (Communaute Financiere Africaine) franc = 100 centimes Main exports: Cotton, animal products, gold GNI per capita: US $400 (World Bank, 2006) Direction du Tourisme et de lHôtellerie BP 624, Ouagadougou 01, Bu